Bio-Reference Laboratories (Nasdaq: BRLI) reported earnings on Aug. 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended July 31 (Q3), Bio-Reference Laboratories met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share increased significantly.

Gross margins dropped, operating margins grew, net margins improved.

Revenue details
Bio-Reference Laboratories tallied revenue of $172.3 million. The six analysts polled by S&P Capital IQ predicted a top line of $173.1 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $148.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.45. The six earnings estimates compiled by S&P Capital IQ anticipated $0.42 per share. GAAP EPS of $0.45 for Q3 were 25% higher than the prior-year quarter's $0.36 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 49.9%, 160 basis points worse than the prior-year quarter. Operating margin was 13.2%, 80 basis points better than the prior-year quarter. Net margin was 7.3%, 50 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $175.7 million. On the bottom line, the average EPS estimate is $0.46.

Next year's average estimate for revenue is $661.7 million. The average EPS estimate is $1.51.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 309 members out of 329 rating the stock outperform, and 20 members rating it underperform. Among 100 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 95 give Bio-Reference Laboratories a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $28.40.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.